22-Oxacalcitriol (OCT) is one of several new analogs of vitamin D that retain many of the therapeutically useful properties of 1,25-dihydroxyvitamin Ds [1,,D,], but have much less calcemic activity. In the present study we examined the actions of OCT on intestinal calcium absorption and calbindin D9k mRNA in vitamin Ddeficient rats. After ip injection of OCT (1 rg/kg), calcium absorption increased significantly by 2 h and was maximal at 4 h (2.5-fold above control), but returned to pretreatment levels by 16 h. In contrast, the same dose of 1,25-(OH)2D3 caused a 3-fold increase in calcium absorption, which lasted more than 48 h. The transient effect of OCT on calcium absorption was also observed when the analog was infused at a dose of 1 rg/kg.day for 3 days. At the end of the infusion period, calcium absorption was 3-fold higher than that in vehicle-infused controls, but fell to pretreatment levels by 24 h after removing the minipumps. The time courses for induction of calbindin D9k mRNA were similar for OCT and 1,25-(OH)zDs, with no change observed until more than 4 h after injection. However, calbindin mRNA levels returned to pretreatment values more rapidly in the OCT-treated rats. Consistent with these findings, we observed that a 1 pg/kg dose of [3H] OCT was completely cleared by 4-6 h after injection. This was paralleled by a loss of VHlOCT associated with the intestinal vitamin D receptdr. The rapid clearance of OCT is probably due to ita low affinity for the serum vitamin D-binding protein. This low affinity would also be expected to allow greater accessibility to target cells. In support of this, we found that higher amounts of OCT than 1,25-(OH)*D3 were associated with the intestinal vitamin D receptor after the injection of several doses of these tritiated ligands. In summary, our results indicate that the pharmacokinetic properties of OCT are responsible at least in part for its low calcemic activity. Furthermore, comparison of the transient elevation of calcium absorption by OCT with ita more prolonged effects on PTH and calbindin D9k indicates that each action of vitamin D compounds has a distinct biological half-life. The short circulating half-life of OCT can exploit these differences to provide a therapeutic advantage in the treatment of vitamin D-responsive diseases. (Endocrinology 133: 1158(Endocrinology 133: -1164(Endocrinology 133: ,1993 
T HE PRIMARY function of vitamin D is to stimulate the intestinal absorption of calcium in response to hypocalcemic stress. This enhancement occurs mainly in the duodenum and is mediated by the activated form of the vitamin, 1,25dihydroxyvitamin D [1,25-(OH),D,] (l-3). Three mechanisms for the absorption of calcium have been described. In the absence of vitamin D, calcium is absorbed mainly by a passive paracellular route, in which the rate of calcium absorption increases linearly with increasing luminal calcium. Vitamin D-dependent calcium transport is a transcellular process that can be saturated by high luminal calcium concentrations. When vitamin D-deficient animals are given 1,25-(OH)2D3, increases in calcium transport require several hours to become apparent. In contrast, using the isolated perfused duodenum technique, changes in calcium fluxes have been observed in vitamin D-replete animals within minutes after the introduction of 1,25-(OH)2D3 in the perfusate (4). This process, termed transcaltachia, is not observed in vitamin D-deficient animals. It is likely that genomically encoded vitamin D-dependent proteins are required for the rapid nongenomic actions of 1,25-(OH)*D3 on calcium flux. A number of vitamin D-dependent proteins have been iden-tified in the duodenum, including the well studied calbindin (5). The exact roles of these proteins in calcium movement are not fully understood.
Recent development of vitamin D analogs with selective activities has provided a new approach for studying the mechanism for vitamin D-dependent calcium transport. Several of these analogs retain the cell-differentiating activity of 1,25-(OH)2D3, but have very little calcemic activity, suggesting a resistance of bone and intestine to these compounds (6-10). The reason for the selective actions of these analogs is not clear. However, an important clue was provided by Okano and co-workers (ll) , who reported that one of these analogs, 22-oxa-1,25-(OH)2D3 (22-oxacalcitriol or OCT), had a very low affinity for the serum vitamin D-binding protein (DBP). This property is shared by the several other analogs with properties similar to those of OCT (12, 13) . Furthermore, as predicted by its low affinity for DBP, OCT was found to be rapidly cleared in viva and more accessible to target cells in culture (12). Despite its rapid clearance, OCT is as active as 1,25-(OH)2D3 in suppressing PTH synthesis in rats (14) and more active in enhancing the immune response in mice (15) and suppressing the growth of mammary carcinoma cells in mice (16), indicating an apparent tissue-specific response to this analog.
In the present study, we have directly examined the actions of OCT in the duodenum. Our results revealed that although OCT has a prolonged effect on calbindin D9k mRNA, it has only a transient effect on intestinal sistent with its rapid clearance. 
Animals
Male weanling Sprague-Dawley rats were maintained for 6 weeks on a vitamin D-deficient diet containing 0.4% calcium and 0.3% phosphorus (TD 86487, Teklad, Madison, WI) . The rats were placed on a vitamin D-deficient, 0.02% calcium diet (Teklad TD 90407) for 2 days before treatment with the vitamin D compounds. At the time of the experiment, the rats weighed approximately 250 g. The total serum calcium level before treatment was 4.96 + 0.29 mg/dl. Plasma 25-hydroxyvitamin Da was undetectable (~0.3 rig/ml) in these rats, as assessed by HPLC purification and competitive binding assay. 1,25-(OH)zDa levels were markedly reduced (27 + 3 us. 40 to 60 pg/ml in normal rats). For the dose-response and time-course studies, OCT and 1,25-(OHhD3 were administered ip in 200 ~1 propylene glycol. In another experiment, OCT and 1,25-(OHhD, were administered in propylene glycol at a dose of 1 rg/kg BW by SC infusion using osmotic minipumps (model 2002, Alzet Corp., Palo Alto, CA).
Intestinal calcium transport
The rate of intestinal calcium transport was measured at the specified time after treatment by a modification of the isolated duodenal loop method (17) . The first 6 cm of the small intestine distal to the pyloric sphincter were flushed twice with 12 ml cold saline, tied off, and filled with 0.6 ml transport buffer [30 mu Tris-HCl (pH 7.4), 10 rn~ fructose, 125 mu NaCl, 10 mM CaCl*, and 5 rCi/ml "Ca+']. After 10 min, the rats were exsanguinated, and the serum was analyzed for "Ca+*. In this protocol, the appearance of "Ca" in the blood increased linearly for at least 20 min, and therefore, the 10 min value represented a true rate of intestinal calcium absorption.
Assay of calbindin D9k mRNA
After the rats were exsanguinated, the duodenal mucosa was scraped and homogenized into 6 ml RNAzol (Cinna-Biotecx, Friendswood, TX). RNA was prepared as described by the manufacturer. Total RNA (10 rg) was separated on a 1.2% agarose gel and transferred to a nylon membrane (MS1 Magnagraph, Fisher Scientific, Pittsburgh, PA) by capillary action. RNA was &o&-linked to the membranesby exRosure io UV lieht (Stratalinker 2400, Strataeene. La lolla. CA) and urehvbridized in 7% sodium dodecyl sulfate (SDS), 6.5 b sodium phos'phate (pH 7), and 1 rn~ EDTA at 65 C for 4 h. Random prime-labeled cDNAs for calbindin D9k and glyceraldehyde 3-phosphate dehydrogenase (GAPDH; lo6 cpm/ml) were added, and hybridization was carried out at 65 C for 16 h. The membranes were washed twice at 65 C for 30 min with 5% SDS, 40 mu sodium phosphate (pH 7), and 1 mu EDTA and twice at 65 C for 30 min with 1% SDS in 40 mu sodium phosphate (pH 7.4) and 1 mu EDTA. The membranes were exposed to x-ray film (Hyperfilm MI', Amersham, Arlington Heights, IL), and the calbindin mRNA bands were quantified with a scanning densitometer (EC Apparatus Corp., St. Petersberg, FL).
Clearance of OCT and 1,25-(OH)2D3
Vitamin D-deficient rats were placed on the low calcium diet for 2 days and then injected ip with [2-3H]OCT or 1,25-(OH)2- [26,27-3H]D3 (0.5, 1, or 2 pg/kg BW; 0.5 pCi/rat). At the specified times, the animals were killed by exsanguination under chloral hydrate anesthesia (360 mg/kg). Blood plasma (1 ml) was spiked with 250 ng radioinert OCT or 1,25-(OHhD3 standard and extracted with C-18 silica cartridges by the method of Reinhardt et al. (IS) . The acetonitrile fraction was dried and analyzed by normal phase HPLC using hexane+opropanol(92:8).
Radioactivity eluting with standard OCT or 1,25-(OH)zDs was determined, corrected for recovery based on the area of the UV peak of the standard, and expressed as picograms of OCT or 1,25-(OH)zDa per ml serum.
In viva labeling of intestinal vitamin D receptor (VDR)
The duodena of the rats injected with [2-3H]OCT or 1,25-(OH)*-J26,27-3H1Ds were flushed twice with 12 ml cold saline containine soybean t&sin inhibitor (STI; 200 pg/rnl) and slit lengthwise, and thg mucosa was scraped with a chilled microscope slide. The mucosa was resuspended in 20 ml saline-ST1 and centrifuged at 200 X g for 10 min. This wash was repeated, and the mucosal pellet was homogenized in 10 ml TED1 buffer [lo mu Tris-HCl (pH ?'.4), 1.5 mu EDNA, 5 rrt~ dithiothreitol, and 200 &ml STIl. Nuclei were isolated bv centrifueation V.
at 500 X g for 10 min. The pellet was resuspended 'm 10 ml"TED1 containing 0.5% Triton X-100 and centrifuged at 5000 x g for 10 min. The Triton X-100 wash was repeated twice, and the final chromatin pellet was resuspended in 2 ml TED1 containing 300 mu KC1 (final concentration). One milliliter was mixed with 9 ml ScintiVerse BD (Fisher Scientific) and counted for tritium in a Beckman LS-2800 scintillation counter (Palo Alto, CA). Another aliouot was analyzed for DNA (19) . HPLC analysis of samples from rats *treated with ihe 2 pg/kg dose of J3H10CT or 1,25-(OHh-13H1D2 was oerformed exactlv as described for the'serum samples (see above) and 'confirmed that ai least 75% of the hitium present in the sample coeluted with standard OCT or 1,25-(OHhD3, respectively (data not shown).
To confirm that the [3H]OCT and 1,25-(0H)~-[~HlD~ in these samples were bound to the VDR, sucrose gradient analysis was performed. The chromatin suspensions were centrifuged at 100,000 X g for 60 min, and an aliquot of the supematant (200 ~1) was layered over a 5-20% sucrose gradient in TED-300 mu KCl. The gradients (12 ml total volume) were centrifuged at 40,000 rpm in an SW-40 rotor (Beckman Instruments) for 40 h. Fractions of 15 drops were collected from the bottom of the gradients, mixed with 4 ml ScintiVerse BD, and counted for tritium. The tritium peak in each sample was found to sediment just above the ovalbumin standard (3.7S), confiig that the ['H]OCT and 1,25-(OH)*-["HID, were bound to the duodenal VDR (data not shown).
Statistics
All data are expressed as the mean f SEM, and experimental groups were compared by analysis of variance.
Results
We examined the time course of the action of OCT and 1,25-(OH)*D3 on intestinal calcium absorption. Vitamin Ddeficient rats were injected with 1 pg/kg OCT or 1,25-(OH)*D3, and calcium transport was measured at 2, 4, 8, 16, 24, and 48 h later. Figure 1 shows that this dose of OCT stimulated calcium absorption significantly by 2 h (P < 0.01). Transport appeared maximal at 4 h (P < 0.05), although the transport rates at 2, 4, and 8 h were not different from each other. By 16 h after OCT injection, calcium absorption had returned to pretreatment levels. The slight increase at 24 h was not a consistent finding. In contrast, the increase in calcium transport after the same dose of 1,25-(OHhD3 was delayed slightly and was much more prolonged. Calcium transport after 1,25-(OHbD3 injection was not different from the control value at 2 h, but increased by 2.5-fold by 8 h, with a further increase of 3-fold by 24 h. With this dose of 1,25-(OHhD3, maximal enhancement of calcium absorption was maintained for at least 48 h. The transient stimulation of calcium transport by OCT was confirmed by infusing OCT with osmotic minipumps at a dose of 1 pg/kg . day. Three days of OCT infusion increased calcium uptake 3-fold compared to that in vehicle-infused controls (Fig. 2) . This was similar to the increase achieved by infusion of the same dose of 1,25-(OHhD3. Figure 2 also shows that by 24 h after removal of the minipumps, calcium absorption dropped substantially in the OCT-infused rats, but remained elevated in the rats that had been infused with 1,25-(OHhD3. These results confirm that the effects of OCT on calcium absorption are short-lived.
The time courses for the induction of calbindin D9K mRNA by OCT and 1,25-(OH),D3 (1 pg/kg) are shown in Fig. 3 . Both OCT and 1,25-(OH)2D3 increased calbindin D9k mRNA levels after 8 h. The data in Fig. 3 injection and 5, 10, 15, 20, 30, 60, 120, 240, 480 , and 960 min after [3H]OCT injection. The time course is shown in Fig. 4. OCT reached a maximal level of 1.8 ng/ ml in the blood by 15 min and was completely cleared by 4 h. In contrast, much higher levels of 1,25-(OH)*D3 were achieved; the maximal level at 2 h was 8.3 rig/ml. Disappearance of 1,25-(OHhD3 was slower than that of OCT.
The time course for binding of [3H]OCT and 1,25-(OHh-[3H]D3 to the duodenal VDR of these rats is shown in Fig. 5 . The time course of binding of each ligand closely parallels its serum levels. However, maximal levels of binding were much higher for OCT (3.5 pmol/mg DNA at 30 min) than for 1,25-(OHbD3 (1.7 pmol/mg DNA at 2 h). Thus, despite the lower maximal levels achieved in the blood, OCT appeared to be more accessible to the intestinal receptor.
A dose-response study was performed using lower (0.5 rg/kg) and higher (2 pg/kg) doses of OCT and 1,25-(OH)*D3.
[3H]OCT in plasma and associated with the duodenal VDR was measured 30 min postinjection. The data are expressed as picomoles of OCT-or 1,25-(OH)2D3-associated VDR per mg DNA. Data are presented as the mean + SD (n = 3).
were chosen to give maximal levels of binding for both ligands, maximal plasma levels of 1,25-(OH)2D3, and nearmaximal plasma levels of OCT. The plasma levels of the two compounds are shown in Fig. 6 . The levels of both OCT and 1,25-(OHhD3 increased linearly with dose. A linear dose response was also observed for binding of both ligands to the duodenal VDR (Fig. 7) . These data clearly show that OCT is much more accessible to the duodenal VDR.
Discussion
In the present study, we examined the calcemic actions of OCT in the intestine of vitamin D-deficient rats. We found that OCT is capable of stimulating calcium absorption, but this effect is only transient. In contrast, the same dose of 1,25-(OHhD3 caused a prolonged elevation of calcium transport. The different responses of these two vitamin D compounds are probably related to their very different pharma- The data are expressed as picomoles of OCT-or 1,25-(OH)pD3-associated VDR per mg DNA. Data are presented as the mean + SD (n = 3).
cokinetics. As shown in Fig. 4 , by 4 h after injection of a 1 rg/kg dose, nearly all of the OCT had been cleared. Although much of this clearance is due to rapid excretion of OCT metabolites in the bile (Nishii, Y., personal communication), uptake into target tissues also contributes to the disappearance from the circulation. However, the loss of OCT from the blood was paralleled by a loss of receptor-associated OCT in the duodenum. The enhanced calcium transport began to return to pretreatment levels after that time. It is likely that the slower disappearance of 1,25-(OHhD3 from the circulation results in its more prolonged action on calcium transport, but additional factors may also be involved.
A pharmacokinetic explanation for the disparate actions of OCT and 1,25-(OH)2D3 in the intestine would not be unexpected considering the previously reported low affinity of the analog for the serum DBP (11, 12) . This low affinity leads to rapid clearance of OCT and very likely limits the Endo. 1993 Voll33. No 3 duration of its effect on calcium transport. Another consequence of low DBP affinity would be a higher proportion of OCT compared to 1,25-(OH)*D3 in the unbound form. Several investigators have shown that DBP (or whole serum) limits access of 1,25-(OH)2D3 to cells in culture (20, 21) . In the present study, we found that an analog of 1,25-(OH)2D3 with lower affinity for DBP is more accessible to target cells in vim. Higher amounts of OCT were associated with intestinal VDR despite the lower peak levels in the blood and a lower affinity for the VDR (measured in vitro). These data provide in vim data to support a role for DBP in limiting the cellular uptake and action of 1,25-(OH)*D3. In addition, the lower DBP affinity and higher percent free OCT may explain its more rapid effect on calcium absorption. The rapid fall in intestinal calcium absorption after OCT clearance indicated the existence of a short-lived factor(s) that is essential for maintaining the increased rate of calcium transport. Calbindin D9k does not appear to be this factor. After OCT administration, the levels of calbindin D9k mRNA remained elevated when calcium transport returned to control levels. The role of calbindin in intestinal calcium absorption is not well defined. Attempts have been made to assign a role for calbindin on the basis of its temporal relationship with calcium absorption after treatment with 1,25-(OH)2D3. Although several groups have found that calbindin levels increase before or at the same times as calcium absorption (22-25), others (26) (27) (28) have observed that calbindin increases after calcium transport is stimulated. Under our conditions, calbindin D9k did not appear to increase until after calcium transport was elevated. However, Dupret et al. (25) observed a transient increase in calbindin D9k within 15 min after ip administration of 1,25-(OH)2D3 to vitamin D-deficient rats. The spike in calbindin D9k mRNA may play a role in the increased calcium absorption within 2 h of OCT administration. Dissociation of calbindin induction and calcium absorption using vitamin D analogs was also reported by Krisinger et al. (29) . In contrast to our results with OCT, they found that side-chain homologs of 1,25-(OH)2D3 could induce calbindin D9k mRNA with not even a transient effect on intestinal calcium transport. It is unclear whether this represents distinctly different properties of these 24-homo analogs, a dose insufficient to have any effect on transport, or an extremely rapid clearance of these analogs. These data obtained with vitamin D analogs provide new insights into the role of calbindin D9k in the mechanism of 1,25-(OH)2D3-stimulated calcium absorption,
The much more prolonged effect of OCT on calbindin, compared to that on calcium transport, is noteworthy. We have found that other genomic actions of OCT have similar time courses. OCT is capable of suppressing 1,25-(OHhD3 synthesis and inducing its degradation (29). Despite the rapid clearance of OCT, serum 1,25-(OH)2D3 levels and renai lcuhydroxylase activity remained suppressed for 2-3 days after administration (30, 31) . The inhibition of 1,25-(OH)2D3 by OCT may result in part from the suppressive action of the analog on PTH secretion. We found that PTH levels in uremic dogs remain below pretreatment levels for 2-3 days after a single injection of OCT (10). Thus, the time course for induction of calbindin is similar to that for other genomic actions of OCT. It is the rapid recovery of calcium transport to pretreatment levels that is unique.
Our time course for calcium transport after 1,25-(OH)*D3 treatment differs from the biphasic response reported by Halloran and DeLuca (32). These researchers observed an initial peak of transport at 6 h, followed by a nadir at 12 h and a second increase to a plateau at 24 h. In their study, Halloran and DeLuca administered 1,25-(OH)zD3 iv, whereas in the present study, the vitamin D compounds were administered ip. The slow absorption of 1,25-(OH)2D3 from the peritoneal cavity in our experiments probably prevented resolution of the two processes. The later prolonged phase observed by Halloran and DeLuca was proposed to be due to migration up the villi of cells that had been in the villus crypt at the time of 1,25-(OH)2D3 administration. The time course of calcium transport after OCT administration gave only a single peak at 4-8 h. It is possible that OCT is unable to support this second, more prolonged phase. Further experiments will be necessary to determine the differentiating activity of OCT in the intestine.
The results of this study support the hypothesis that pharmacokinetics are responsible for the very low calcemic activity of OCT and possibly the other noncalcemic vitamin D analogs. However, other explanations cannot be ruled out. Recent reports have indicated that OCT and other analogs with properties similar to those of OCT (i.e. high differentiating activity, low calcemic activity, high affinity for the VDR, and low affinity for DBP) may be unable to support the nongenomic actions of 1,25-(OH)*D3. OCT has been shown to be incapable of mimicking the ability of 1,25-(OH)2D3 to increase cytosolic calcium levels in ROS 17/2.8 cells (33). In addition, several other analogs of 1,25-(OH)2D3 with modifications in the side-chain and D-ring were reported to have minimal effect on cytosolic calcium in ROS 17/2.8 cells (34).
1,25-(OH)*D3 has been shown to trigger a rapid influx of calcium through a voltage-regulated calcium channel on the basolateral surface of enterocytes (35, 36) . Other agents that stimulate calcium influx through this channel also increase the transcaltachia pathway (37). Several vitamin D analogs with low calcemic activity have been shown to be relatively inactive in stimulating transcaltachia (37). On the other hand, several analogs of 25-hydroxyvitamin DJ that have poor affinity for the nuclear VDR were active in stimulating intracellular calcium (34) and transcaltachia (37). These data suggest the existence of a second VDR that is responsible for the rapid nongenomic actions of vitamin D compounds. The actions of OCT on cytosolic calcium in the enterocyte and transcaltachia have not been reported.
Other mechanisms for the selectivity of noncalcemic analogs are also possible. Multiple forms of the VDR could exist, and some of these may not recognize various analogs of 1,25-(OH)2D3. Little is known about the in vim metabolism of these analogs. Tissue-specific catabolism or activation could play a role in their selectivity.
In summary, our results show the following. 1) OCT is capable of stimulating intestinal calcium transport, but this effect is short-lived. This finding is consistent with the rapid clearance of OCT from the circulation and the ensuing loss of OCT-VDR complexes. 2) Calbindin D9K mRNA does not increase following OCT treatment until after calcium transport is maximal and remains elevated after calcium transport returns to pretreatment levels.
3) The low affinity of OCT for serum DBP not only results in rapid clearance of this analog, but also makes it more accessible to target tissues. 4) The rate of calcium transport returns to pretreatment levels with a few hours after OCT disappears from the circulation. This differs from the more prolonged effects, such as induction of calbindin D9K mRNA and 24-hydroxylase activity and suppression of PTH secretion and lcr-hydroxylase activity, which persist for 24-48 h. These findings suggest a fundamental difference between the regulatory mechanisms for calcium transport and these other processes. The short circulating half-life of OCT can exploit these differences to provide a therapeutic advantage in the treatment of vitamin D-responsive diseases.
